Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Technetium (99mTc) macrosalb (commonly referred to as technetium-99m albumin macroaggregates or Tc-99m MAA) is a diagnostic radiopharmaceutical used in nuclear medicine. It consists of human serum albumin that has been denatured and aggregated into particles of controlled size (typically 10 to 90 micrometers) and labeled with the gamma-emitting radionuclide technetium-99m. Upon intravenous injection, the macroaggregates are physically trapped by microembolization in the pulmonary capillary bed, allowing for the visualization of pulmonary perfusion via single-photon emission computed tomography (SPECT) or planar scintigraphy. It is primarily indicated for lung perfusion scintigraphy as an adjunct in the evaluation of pulmonary perfusion (e.g., for diagnosing pulmonary embolism) in both adult and pediatric patients. It is also used to evaluate the patency of peritoneovenous (LeVeen) shunts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on technetium (99mTc) macrosalb (Bracco Group).